Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A... Cardiovasc Intervent Radiol (2017) 40:1440–1446 DOI 10.1007/s00270-017-1662-9 CLINICAL INVESTIGATION NON-VASCULAR INTERVENTIONS Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study 1 2 2 3 • • • • Gianluigi Patelli Antonio Ranieri Aurelio Paganelli Giovanni Mauri Claudio Maurizio Pacella Received: 18 December 2016 / Accepted: 21 April 2017 / Published online: 4 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract 10,522 ± 3290.5 J, mean hospital stay 1.5 ± 0.4 days, and Purpose To assess the feasibility and safety of transper- mean catheterization time 17.3 ± 10.0 days. At 3 months, ineal laser ablation (TPLA) for treating benign prostatic IPSS improved from 21.9 to 10.7 (P\ 0.001), QoL from hyperplasia (BPH). 4.7 ± 0.6 to 2.1 ± 1.2 (P\ 0.001), Q from 7.6 to 13.3 max Materials and Methods Institutional review board approval mL/s (P = 0.001), PVR from 199.9 ± 147.3to81.5 ± 97.8 was obtained for this prospective non-randomized trial. (P\ 0.001), and mean prostate volume from 69.8 to 54.8 mL Eightteen patients (age 71.7 ± 9.4 years) with urinary (P\ 0.001). symptoms secondary to BPH underwent TPLA under local Conclusions TPLA is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study

Loading next page...
1
 
/lp/springer_journal/transperineal-laser-ablation-for-percutaneous-treatment-of-benign-qsF2xT4WbX

References (25)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
DOI
10.1007/s00270-017-1662-9
pmid
28474112
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1440–1446 DOI 10.1007/s00270-017-1662-9 CLINICAL INVESTIGATION NON-VASCULAR INTERVENTIONS Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study 1 2 2 3 • • • • Gianluigi Patelli Antonio Ranieri Aurelio Paganelli Giovanni Mauri Claudio Maurizio Pacella Received: 18 December 2016 / Accepted: 21 April 2017 / Published online: 4 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract 10,522 ± 3290.5 J, mean hospital stay 1.5 ± 0.4 days, and Purpose To assess the feasibility and safety of transper- mean catheterization time 17.3 ± 10.0 days. At 3 months, ineal laser ablation (TPLA) for treating benign prostatic IPSS improved from 21.9 to 10.7 (P\ 0.001), QoL from hyperplasia (BPH). 4.7 ± 0.6 to 2.1 ± 1.2 (P\ 0.001), Q from 7.6 to 13.3 max Materials and Methods Institutional review board approval mL/s (P = 0.001), PVR from 199.9 ± 147.3to81.5 ± 97.8 was obtained for this prospective non-randomized trial. (P\ 0.001), and mean prostate volume from 69.8 to 54.8 mL Eightteen patients (age 71.7 ± 9.4 years) with urinary (P\ 0.001). symptoms secondary to BPH underwent TPLA under local Conclusions TPLA is

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: May 4, 2017

There are no references for this article.